Predictive Oncology Research and Development Expenses 2010-2025 | POAI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Predictive Oncology research and development expenses from 2010 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.

Predictive Oncology Research and Development Expenses 2010-2025 | POAI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Predictive Oncology research and development expenses from 2010 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Veeva Systems (VEEV)	$47.5B
Hims & Hers Health (HIMS)	$12.9B
Doximity (DOCS)	$11.4B
Tempus AI (TEM)	$11.2B
IRhythm Technologies (IRTC)	$4.3B
Inspire Medical Systems (INSP)	$3.8B
Hinge Health (HNGE)	$3.6B
Privia Health (PRVA)	$2.4B
10x Genomics (TXG)	$1.7B
Schrodinger (SDGR)	$1.6B
Phreesia (PHR)	$1.6B
Azenta (AZTA)	$1.6B
Enovis (ENOV)	$1.6B
Clover Health Investments (CLOV)	$1.5B
Omnicell (OMCL)	$1.3B
Evolent Health (EVH)	$1.2B
Claritev (CTEV)	$652M
Fulgent Genetics (FLGT)	$559M
Standard BioTools (LAB)	$532M
Veradigm (MDRX)	$503M
Butterfly Network (BFLY)	$487M
Talkspace (TALK)	$421M
TruBridge (TBRG)	$353M
Outset Medical (OM)	$328M
Health Catalyst (HCAT)	$270M
Nyxoah SA (NYXH)	$258M
SOPHiA GENETICS SA (SOPH)	$240M
CapsoVision (CV)	$185M
Zepp Health (ZEPP)	$161M
KORU Medical Systems (KRMD)	$160M